S-Acetyl Glutathione and Performance Recovery in Soccer
2026年7月1日 更新者：Dimitrios Draganidis、University of Thessaly
Pharmacodynamics & Pharmacokinetics Study of S-Acetyl Glutathione in Highly Trained Soccer Players
Soccer players display elevated inflammatory and oxidative stress markers combined with reduced soccer specific performance over a 72-hour period.
However, in modern soccer, players participate very often in 2 or 3 matches within a week, with a recovery period of 72 hours between successive matches, that is insufficient to restore skeletal muscle homeostasis and performance.
Of note, reduced glutathione (GSH) levels, a tripeptide consisting of the amino acids cysteine, glycine and glutamic acid, are substantially reduced during the 72-hour recovery period after a match because of the trauma-related acute inflammatory and oxidative stress response.
GSH availability is a crucial regulator of cellular redox status, affecting numerous intracellular and physiological processes such as redox signalling, immunoregulation and muscle metabolism.
Indeed, enhanced GSH availability following muscle damaging exercise has been shown to be beneficial for skeletal muscle and performance recovery by mitigating the inflammatory and oxidative stress response.
Thus, the enhancement of GSH availability through dietary interventions would be a promising strategy to accelerate skeletal muscle and performance recovery following a soccer game.
S-Acetyl Glutathione (SAG) is a glutathione precursor with enhanced absorption kinetics due to chemical S-acetylation of the thiol group on the cysteinyl amino acid of GSH and oral administration of SAG has been shown to be more effective in restoring intracellular glutathione levels compared to oral glutathione.
The aim of this study is to (i) perform a pharmacokinetic assessment of 200 mg/day vs 500 mg/day of SAG during a 7-day supplementation period (pre-loading) and (ii) to establish the pharmacodynamic effect of the two dosages at 24, 48 and 72h following a 90-minute official soccer match.
調査の概要
状態
まだ募集していません
詳細な説明
Following baseline testing [including assessment of anthropometrics, body composition (via DXA instrumentation) and physical performance (cardiorespiratory fitness, drop jump and countermovement jump performance, repeated sprint anility, isokinetic peak torque)], 20 well-trained, soccer players will participate in three trials, receiving daily (i) 200 mg SAG, (ii) 500 mg SAG or (iii) Placebo, according to a randomized, double-blind, crossover, repeated-measures design. The duration of each trial will be 11 days, including a 7-day pre-loading period (days 1 -7), a match day (day 8) and 3 consecutive recovery days after the match (days 9-11). Between trials a 3-week washout period will be implemented.
Pre-loading period: During the 7-day pre-loading period players will participate daily in training sessions according to a soccer-specific weekly training schedule, while receiving the respective supplement. Blood samples will be collected on day 1 and day 7 while daily nutrient intake (via 7-day diet recalls), physical activity level (via accelerometry) and training load (via global positioning system instrumentation during training sessions) will be monitored daily.
Match day: On match day, players will participate in an official 90-min soccer match. Field activity (total distance, average and maximum speed, high intensity running, high speed running, accelerations, decelerations) and heart rate (mean and maximum heart rate) will be continuously monitored using global positioning system (GPS) and heart rate monitors, respectively.
Recovery days: During the 3-day recovery period after the match, players will participate daily in (i) morning testing sessions and (ii) training sessions in the evening. Testing sessions will include blood sampling and performance measurements including drop jump and countermovement jump performance, repeated sprint anility, isokinetic peak torque and muscle soreness (DOMS). Dietary intake (via a 3-day diet recalls), physical activity level (via accelerometry) and training load (via GPS instrumentation during training sessions) will be monitored daily.
研究の種類
介入
入学 (推定)
20
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Dimitrios Draganidis, PhD
- 電話番号：+30 2431047078
- メール：ddraganidis@uth.gr
研究連絡先のバックアップ
- 名前：Athanasios Poulios, PhD
- 電話番号：+30 2431047053
- メール：athanpoul@gmail.com
研究場所
-
-
Karies
-
Trikala、Karies、ギリシャ、42100
- Department of Physical Education and Sport Science, University of Thessaly
-
コンタクト：
- Ioannis G Fatouros, PhD
- 電話番号：+30 2431047047
- メール：ifatouros@uth.gr
-
コンタクト：
- Athanasios Z Jamurtas, PhD
- 電話番号：+30 24310 47054
- メール：ajamurt@uth.gr
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
はい
説明
Inclusion Criteria:
- participation at elite (top three division leagues) for ≥ 4 years
- no recent history of febrile illness, musculoskeletal problems and metabolic diseases
- no consumption of medications and performance-enhancing supplements (including anti-inflammatory, antioxidants, vitamins and multivitamin supplements) for at least 6 months prior to the study
- participation in at least 5 training sessions and 1 match per week
- non-smokers
Exclusion Criteria:
- musculoskeletal injury
- consumption of medication and performance-enhancing supplements
- illness during the course of the study
- loss of follow-up measurements
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：他の
- 割り当て：ランダム化
- 介入モデル：クロスオーバー割り当て
- マスキング：トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：SAG-200 Trial
Oral administration of S-Acetyl Glutathione (SAG)
|
Participants will be supplemented daily with 200 mg of S-acetyl glutathione, orally, over the 11-day experimental period.
|
|
実験的：SAG-500 Trial
Oral administration of S-Acetyl Glutathione (SAG)
|
Participants will be supplemented daily with 500 mg of S-acetyl glutathione, orally, over the 11-day experimental period.
|
|
プラセボコンパレーター：Placebo Trial
Oral administration of placebo
|
Participants will be supplemented daily with placebo, orally, over the 11-day experimental period.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in creatine kinase levels
時間枠：Day 1, day 7, day 9, day 10 and day 11
|
Creatine kinase concentration will be measured in serum using a Clinical Chemistry Analyzer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in myoglobin levels
時間枠：Day 1, day 7, day 9, day 10 and day 11
|
Myoglobin concentration will be measured in serum using a Clinical Chemistry Analyzer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in reduced glutathione
時間枠：Day 1, day 7, day 9, day 10 and day 11
|
Reduced glutathione will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in oxidized glutathione
時間枠：Day 1, day 7, day 9, day 10 and day 11
|
Oxidized glutathione will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in glutathione reductase activity
時間枠：Day 1, day 7, day 9, day 10 and day 11
|
Glutathione reductase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in glutathione peroxidase activity
時間枠：Day 1, day 7, day 9, day 10 and day 11.
|
Glutathione peroxidase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11.
|
|
Change in catalase activity
時間枠：Day 1, day 7, day 9, day 10 and day 11
|
Catalase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in superoxide dismutase activity
時間枠：Day 1, day 7, day 9, day 10 and day 11
|
Superoxide dismutase activity will be photometrically determined in red blood cell lysates using a spectrophotometer
|
Day 1, day 7, day 9, day 10 and day 11
|
|
Change in maximal voluntary isometric contraction
時間枠：Day 1, day 9, day 10 and day 11
|
Maximal voluntary isometric contraction will be assessed at a 60o knee joint angle, in both dominant and non-dominant limb, using an isokinetic dynamometer
|
Day 1, day 9, day 10 and day 11
|
|
Change in maximal peak torque
時間枠：Day 1, day 9, day 10 and day 11
|
Maximal concentric and eccentric peak torque at 60o/s of the knee extensors and flexors in both dominant and non-dominant limb, will be assessed on an isokinetic dynamometer
|
Day 1, day 9, day 10 and day 11
|
|
Change in jumping performance
時間枠：Day 1, day 9, day 10 and day11
|
Countermovement jump and drop jump performance will be tested using an optical measurement system consisting of a transmitting and receiving bar
|
Day 1, day 9, day 10 and day11
|
|
Change in repeated sprint ability
時間枠：Day 1, day 9, day 10 and day 11
|
Repeated sprint ability will be assessed by performing 5x25 m sprints interspersed by a 25-seconds recovery period using infrared photocells
|
Day 1, day 9, day 10 and day 11
|
|
Change in delayed onset muscle soreness (DOMS)
時間枠：Day 1, day 9, day 10 and day 11
|
DOMS will be assessed using a 10-scale visual analogue scale
|
Day 1, day 9, day 10 and day 11
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in total distance covered
時間枠：Daily throughout the 11-day experimental period
|
Total distance (km) covered during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in internal load
時間枠：Daily throughout the 11-day experimental period
|
Heart rate during training sessions and the match will be monitored using heart rate monitors
|
Daily throughout the 11-day experimental period
|
|
Change in dietary intake
時間枠：Daily throughout the 11-day experimental period
|
Dietary intake will be assessed using diet recalls
|
Daily throughout the 11-day experimental period
|
|
Change in time spent in moderate-to-vigorous physical activity
時間枠：Daily throughout the 11-day experimental period
|
The time (minutes) spent in moderate-to-vigorous physical activity on a daily basis will be monitored using accelerometers
|
Daily throughout the 11-day experimental period
|
|
Change in distance covered with high-intensity running
時間枠：Daily throughout the 11-day experimental period
|
Distance (km) covered with high-intensity running during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in distance covered with sprinting
時間枠：Daily throughout the 11-day experimental period
|
Distance (km) covered with high-intensity sprinting during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in accelerations
時間枠：Daily throughout the 11-day experimental period
|
The number of accelerations performed during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in decelerations
時間枠：Daily throughout the 11-day experimental period
|
The number of decelerations performed during training and match play will be monitored using Global Positioning System (GPS)
|
Daily throughout the 11-day experimental period
|
|
Change in total step count
時間枠：Daily throughout the 11-day experimental period
|
The total number of steps performed daily will be monitored using accelerometers
|
Daily throughout the 11-day experimental period
|
|
Change in physical activity-related energy expenditure
時間枠：Daily throughout the 11-day experimental period
|
Energy expenditure (kcal) related to habitual physical activity will be assessed using accelerometers
|
Daily throughout the 11-day experimental period
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- 主任研究者：Dimitrios Draganidis, PhD、University of Thessaly, Department of Physical Education and Sport Science
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年9月1日
一次修了 (推定)
2026年12月20日
研究の完了 (推定)
2027年1月20日
試験登録日
最初に提出
2026年6月9日
QC基準を満たした最初の提出物
2026年7月1日
最初の投稿 (実際)
2026年7月8日
学習記録の更新
投稿された最後の更新 (実際)
2026年7月8日
QC基準を満たした最後の更新が送信されました
2026年7月1日
最終確認日
2026年5月1日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- UTH-06/13.02.2026
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。